Cancer Therapeutics CRC signs agreement to enable Pfizer to develop novel cancer drugs
24 October 2018
Pictured: CEO of Cancer Therapeutics Brett Carter signing the agreement.
Melbourne-headquartered Cancer Therapeutics CRC (CTx) announced a two-year research collaboration and a license agreement with Pfizer Inc. (NYSE: PFE).
Brett Carter, CEO of CTx, said, “We are very excited to work with a company of Pfizer’s calibre on the progression of these programs. This deal, together with the three prior deals for CTX technology, has the potential to return a billion dollars to Australia.
"Funds that will help support the biomedical sector and that can be ploughed into new drug discovery programs; providing opportunities for the world class team we have developed, and potentially leading to the delivery of new treatments for patients and economic benefits for the nation."
Dr. Robert Abraham, Senior Vice President and Group Head of Pfizer’s Oncology Research & Development Group said: “We are constantly searching the globe for the best science that has the potential to change the way we can treat people with cancer in the future.
"What we have found at CTx with these two chromatin modifying enzyme targets are very promising, differentiated programs that have the potential to provide new treatment options for patients.”
Asked why CTX had achieved such great success, Dr. Ian Street, CTX CSO responded ‘Every new cancer drug starts with a great idea, however what Australia lacked was a good mechanism to convert these ideas into potential new medicines, and this is the niche that CTx has filled’